ElsaLys Biotech, a fast-growing biotechnology company that designs and develops « best-in-disease » therapeutic antibodies that target tumors and their immune and/or vascular microenvironment, today announces new appointments in its top management team, now complete to support the development of its candidates and its future operations.
Catherine Mathis, Liliane Bronstein and David Liens, join ElsaLys Biotech as Chief Operating Officer, Vice President Finance and Chief Medical Officer, respectively.
Catherine Mathis, PharmD, Chief Operating Officer, has over 25 years’ experience in clinical research and regulatory affairs in the pharmaceutical and biotech industries, particularly in the fields of immunology and oncology.
Liliane Bronstein, MSG, Vice President Finance, brings to ElsaLys Biotech solid experience in executive management and over 20 years’ financial experience within high growth innovative companies.
Finally, David Liens, MD, Chief Medical Officer, brings more than 20 years’ experience in the field of drug development and medical affairs in large pharmaceutical groups and biotech growth companies.
"It is a great pleasure to welcome Catherine Mathis and David Liens in our team, at a time when we are increasing the level of our R&D programs and preparing them to enter the clinic. Their respective experience will be essential to drive our accelerated development strategy and we are delighted that they accepted this challenge." states Dr Christine Guillen, CEO and co-founder of ElsaLys Biotech. "Liliane Bronstein’s experience in capital raising, IPO and M&A transactions is also essential to support our growth".
Dr Jacques Mizrahi, VP R&D adds: "With these new talents in the team, ElsaLys Biotech will continue to strengthen its portfolio and above all refine its options of clinical development and the choice of their target poplulations. For anti-CD115, on the one hand, which will have to confirm in patient its differentiating mechanism of action on the tumoral microenvironment and whose anti-fibrotic potential could provide an excellent opportunity for an accelerated proof of principle in patients treated with radiotherapy. For anti-CD160, on the other hand, in particular around its immunomodulator potential and its mechanism of action on NK and T cells; here again, the choice of target populations as well as the design of clinical studies in stand alone or in combotherapy will become of utmost importance. "